JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

474.51 2.98

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

470.92

Max

478.69

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
Winstmarge	-39.75
Werknemers	528
EBITDA	-68M -106M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+47.73% upside

Dividenden
By Dow Jones
Volgende Winsten	19 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.9B 11B
Vorige openingsprijs	471.53
Vorige sluitingsprijs	474.51

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 feb 2026, 23:57 UTC

Marktinformatie

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 feb 2026, 23:47 UTC

Marktinformatie

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 feb 2026, 23:43 UTC

Marktinformatie

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 feb 2026, 23:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 feb 2026, 23:34 UTC

Marktinformatie

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 feb 2026, 23:26 UTC

Marktinformatie

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 feb 2026, 21:43 UTC

Marktinformatie

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 feb 2026, 21:16 UTC

Marktinformatie

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 feb 2026, 21:15 UTC

Marktinformatie

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 feb 2026, 09:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

7 feb 2026, 09:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 feb 2026, 05:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 feb 2026, 02:46 UTC

Acquisities, Fusies, Overnames

Big Money, High Anxiety -- Barrons.com

6 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

6 feb 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

6 feb 2026, 21:40 UTC

Acquisities, Fusies, Overnames

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 feb 2026, 21:22 UTC

Marktinformatie

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 feb 2026, 21:17 UTC

Winsten

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 21:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

6 feb 2026, 21:14 UTC

Acquisities, Fusies, Overnames

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 feb 2026, 21:13 UTC

Winsten

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 feb 2026, 21:13 UTC

Winsten

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 feb 2026, 21:04 UTC

Marktinformatie

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 feb 2026, 20:34 UTC

Winsten

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

47.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 705.56 USD 47.73%

Hoogste 964 USD

Laagste 570 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.